Bilcare Limited (BI)

Small Cap

Bilcare Limited operates in Pharma Packaging, within the Industrials sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers.

₹88.85

-1.81 · -2.00%

Market cap ₹223 Cr

Data qualityFresh enough for analysisQuote updated 19 Oct, 05:50 pm IST

Details

Quote19 Oct, 05:50 pm IST

Base fundamentals06 Oct 2026 · screener

Latest result13 Aug, 10:54 pm IST

Score20 Oct, 04:30 am IST · v4.3-runtime-valuation

Tags02 May 2026

Coverage14/14 · 100%

Valuation2026-07-20 · Rf 6.8% · Industrials P/E 26.2 (n=537)

Technical timing lens

Trend score and candlestick chart

54Neutral

SMA20 +2.9% / mo · MACD −

Stock trend: 56

Sector RS: 50

Sector 3M: -6.3% vs Nifty 500 -5.6%

Industrials FPI tailwindNot confirmed

Latest mapped FPI equity flow was not positive. View sector evidence

Compare peers →

Technical chart

BID candles · FIT view+39.5%

Latest close ₹88.85 on 2026-10-19

Daily history is available from 2026-04-20; the requested 1Y window is partially covered.

Bar

+0.0%

RSI

MACD hist

-1.40

52W pos

61%

2026-10-19O ₹88.85H ₹88.85L ₹88.85C ₹88.85Vol 2,585 sh

Up bar

Down bar

EMA 20

EMA 50

Volume + 20D avg

Result date

RSI(14)

MACD / signal

Market context

Relative performance and chart statistics

Adjusted completed-session prices, rebased to 100

BINifty India ManufacturingNifty 500

BI: +43.3%
Nifty 500: -5.6%
Nifty India Manufacturing: -5.8%
Vs Nifty 500: +48.8 pp

Chart stats

19 Oct 2026

From 52W high: -21.4%
52W range position: 61%
ATR (14): 3.5%
Volume vs 20D: 0.15x
Avg traded value: ₹0.1 Cr
20D price channel: ₹88.9 - ₹113

Quarter ended 30 Jun 2026

Good · 55

Rev +22% YoY · margin expansion · +20% QoQ

Revenue: ₹226 Cr; YoY +21.5%
PAT: ₹15 Cr; YoY NDF
Operating margin: 16.0%; QoQ +700 bps
PAT margin: 6.6%; QoQ +238 bps

Filed 13 Aug 2026Full result & history →

Current-quarter concall

Transcript not linked yet

No source-linked earnings-call transcript is available for this company in the active results quarter.

Search Concall Intelligence

Technical snapshot

Positioning and participation

Insufficient history

Current trend context ranked against all active NSE stocks. It describes the chart; it is not a buy or sell signal.

RS percentile: 89; 20-day rank history unavailable
Stage 2 entry: Insufficient history; A stage read needs at least 170 adjusted daily sessions
Sector rotation: #2; leading · 600 stocks
Industry rotation: #12; leading · 38 stocks

Trend structure

Below 20-DMABelow 50-DMA— 200-DMA

RSI (14)

Weak momentum

MACD

Below signal

Histogram -1.40

Volume participation

0.1x average

Versus 20-session average

20-session position

0% of range

₹88.85 low · ₹113 high

Relative performance

vs Nifty 500

1M: -13.9 pp; stock -17.4%
3M: +48.8 pp; stock +43.3%
6M: +43.1 pp; stock +39.5%
1Y: +43.1 pp; stock +39.5%

From 52W high

-21.4%

High ₹113

52W range position

61%

₹51.62 - ₹113

ATR (14)

3.5%

₹3.12

Avg traded value

₹0.1 Cr

20-session average

Current setup

No confirmed setup attached

Review the chart and detailed technical evidence before drawing a conclusion.

Open detailed technicals →

Research snapshot

What the evidence says now

Weak fundamentals, management evidence is still limited to a financial-only Trust Lite signal, price trend is neutral, and recent execution is weak.

Suggested next step

Check latest quarters

Result consistency is weak; verify whether the thesis is improving or deteriorating.

U-Score

Legacy · WATCHLIST

Fundamental lens: valuation, quality, growth, balance sheet, and cash flow.

Financials

Fundamentals, quarterly history, margins, returns and balance-sheet evidence

Quarter ended 30 Jun 2026

Good · 55/100

Rev +22% YoY · margin expansion · +20% QoQ

Filed 13 Aug 2026

Open results browser →

Metric	This quarter	YoY	QoQ
Revenue	₹226 Cr	+21.5%	+20.2%
EBITDA	₹37 Cr	+236.4%	+117.6%
Operating margin	16.0%	+1000 bps	+700 bps
PAT	₹15 Cr	NDF	+87.5%
PAT margin	6.6%	+1202 bps	+238 bps

NDF means not disclosed in the current structured filing feed. It is intentionally not treated as zero.

Fundamentals

Valuation

P/E: 11.20
P/B: 1.13
EV/EBITDA: 8.78
Market Cap: 223.00Cr

Profitability

ROE: 1.39%
ROCE: 7.06%
ROA: -0.71%
Dividend Y: —

Growth (CAGR)

Revenue 5Y: 3.00%
EPS 5Y: 16.00%
Revenue 3Y: -9.00%
EPS 3Y: 32.00%

Balance Sheet

Debt/Equity: 3.15
Interest Coverage: 0.97×
Altman Z: 1.77
Book Value: 83.60

Cash Flow

FCF Yield: 55.16%
FCF Positive Y: 8/5
OCF: 128.00 Cr
EPS TTM: 6.23

Shareholding

Promoter Hold: 30.01%
Promoter Pledge: 0.00%
Momentum 52W: 68%

Financial History

Updated 20/10/2026

Revenue

₹ Cr

Latest: 226+20.2% vs prev

Net Profit

₹ Cr

Latest: 15.0+87.5% vs prev

ROE is shown only in the Annual view — quarterly equity data isn't published.

Technicals

Trend interpretation, Stage 2, relative strength, volume and indicator evidence

Daily technical trend read

Mixed signals

Signals are conflicting — long-term trend unclear. RSI 41. Wait for confirmation.

SMA20 rising (~2.8% over last month) — short-term momentum positive.
RSI(14) at 41 — falling, no extreme reading.
MACD below signal but histogram contracting — bearish momentum easing.
21% off 52W high · 72% above 52W low.

Mechanical read from the price + indicator series above. Not a recommendation — technical setups can reverse without warning, especially around earnings and macro events.

Nifty 500 leadership

Relative Strength & Trend Stage

RS percentile

Insufficient history

1M return

-17.4%

3M return

+43.3%

6M return

+43.4%

1Y return

RS 1D

RS 20D

Sector rank

Industry rank

#12

Stage evidence

At least 170 daily sessions are required for the trend-stage read.

50-DMA

price below

200-DMA

unavailable

Sector

leading

Industry

leading

Partial-history RS: the 3M and 6M weights are re-normalised because 12M history is unavailable.

Relative-strength line vs Nifty 500 (base 100)

127 observations

19 Oct 2026Value 144.7-0.98%

RS vs Nifty 500145

Valuation & peers

U-Score 44 · legacy U-Score band WATCHLIST · valuation evidence and comparable companies

Distress Watch

Fundamental score breakdown

U band · WATCHLIST

Valuation21/30

Growth15/25

Quality0/20

Balance Sheet0/15

Cash Flow8/10

Piotroski

6/9 (+3)

Penalties

-3

Raw sum

Why this score?

Top U-Score contributors and drags from the latest stored fundamentals.

44/100 · legacy band WATCHLIST

Positive drivers

FCF yield is supportive at 55.2%.
Fair-value margin of safety is positive at 63.7%.
Cash flow contributes 8/10 to the score.

Main drags

Altman Z is 1.8, in distress territory.
Penalty bucket subtracts 3 points.
Quality is weaker at 0/20; verify the latest quarterly trend.

Sector valuation model

Healthcare valuation: PE/EVEBITDA with regulatory and pipeline checks

Healthcare valuation needs both earnings quality and regulatory/pipeline context.

Pharma PE/EVEBITDA

Primary lens

PE and EV/EBITDA adjusted for product mix and R&D/pipeline quality.

Secondary checks

USFDA risk, launch pipeline, margin trend, domestic vs export mix.

Main risk check

Regulatory setbacks or one-off product cycles can distort valuation.

11.2

1.1

EV/EBITDA

8.8

ROE

1.4%

ROCE

7.1%

FCF Yield

55.2%

Debt/Equity

3.1

MoS

+63.7%

Score movement

Stored run vs live recompute

This shows the stored score trend when snapshots exist, and also compares the latest stored nightly score with a live recompute from current fundamentals and price.

Stored run: 20 Oct 2026

v4.3-runtime-valuation

Final score

Previous: 44

Legacy U-Score band

WATCHLIST

Previous: WATCHLIST

Margin of safety

+63.7%

Previous: +63.7%

Score history

12 stored score snapshots. Latest stored move: +0 points.

20 Oct 2026

v4.3-runtime-valuation

Factor attribution

No pillar movement versus the latest stored run. Historical score trend will appear after snapshot storage is enabled.

Modelled fair value

Graham Number

₹108.25

+17.9% MoS

Growth-justified P/E

39.3

Growth-justified Value

₹244.84

+63.7% MoS

PEG

0.50

Comparable companies

Peers

Business-comparable peers in Industrials — ranked by industry, sub-sector, theme-tag overlap, market cap, and U-Score similarity. Green cells mark the best available peer metric in this table.

Compare all ↗

Ticker

Name

Why peer

Score

ROE

MoS

Verdict

WORTHPERI

Small

Worth Peripherals Limited

Rajshree Polypack Limited

Business, management & trust

Growth engines, risks, management commitments and evidence-backed delivery

Business and thesis

Issuer presentation review pending

Bilcare Limited operates in Pharma Packaging, within the Industrials sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers. The structured result feed currently covers the quarter ended 30 Jun 2026. Investor presentations and earnings-call PDFs will be added as issuer-backed evidence before management claims appear here.

Trust Score

54Limited evidence · low confidenceTrust Lite

Trust asks: does management behaviour match later outcomes? Higher is better, but confidence and evidence depth matter as much as the number.

Limited evidence: Claim history is still being built. It ranks around the 13th percentile of the scored universe and 10th percentile within Industrials. Main check: balance sheet trust is weak at 8/100.

This is a financial-behaviour screen, not a claim-tested management reliability verdict.

Computed 05 Sept 2026

management-trust-v1

2 docs text-extracted · 0 concalls text-extracted

Score band

Limited evidence

Financial behaviour is scored, but management claims do not yet have enough outcome checks.

Relative rank

13th percentile

overall median 67 · Industrials: 10th pctile, median 68 · Small: 15th pctile, median 66

Evidence depth

Financial-only

2 documents have extracted text, but claim history is not strong enough yet.

Claim delivery

Outcome history still building

0 claims extracted · No contradicted claim yet

How to read this Trust Score

Limited evidence · low confidence

What it measures

Reliability of management and financial delivery, using financial behaviour only.

Confidence

Treat this as an early read until more concalls and outcomes are matched.

Investor use

Needs extra due diligence; demand valuation comfort and recent improvement.

Read Trust alongside U-Score, result consistency, and technical trend. A cheap stock with weak Trust needs a larger margin of safety; a high Trust score does not make an expensive stock attractive by itself.

Forensic breakdown

Read low sub-scores as due-diligence warnings, not automatic sell signals.

Promoter

strong · holding, pledge, alignment

Cash flow

strong · profit to cash conversion

Balance sheet

weak · leverage and solvency

Discipline

watch · capital discipline

Results

weak · quarterly consistency

Trust positives

▸Promoter pledge is zero.
▸FCF yield is 54%.
▸8 years of positive FCF.

Trust risks

▸Debt/equity is 3.15.
▸Altman Z is 1.77.
▸Interest coverage is 1.0x.
▸ROCE is low at 5.6%.

Trust Lite uses financial behaviour only. Prefer claim-tested Trust when enough concall claims have later outcomes.

Compare Industrials stocks Browse Indian stocks starting with B Explore fundamental stock screeners Browse Indian investment themes

Related companies

Worth Peripherals Limited (WORTHPERI)Beardsell Limited (BEARDSELL)Rajshree Polypack Limited (RPPL)Rollatainers Limited (ROLLT)Antarctica Limited (ANTGRAPHIC)

Important announcements & filings

Latest exchange and company disclosures found within the past two years.

Source: Bse

Open source ↗

Verify on:NSE India ↗

All information is for study purposes only. For investment decisions, consult your financial advisor. See Playbook for methodology.

Bilcare Limited (BI)

Trend score and candlestick chart

Technical chart

Relative performance and chart statistics

What the evidence says now

Financials

Quarter ended 30 Jun 2026

Fundamentals

Valuation

Profitability

Growth (CAGR)

Balance Sheet

Cash Flow

Shareholding

Revenue

Net Profit

Technicals

Daily technical trend read

Relative Strength & Trend Stage

Valuation & peers

Fundamental score breakdown

Why this score?

Positive drivers

Main drags

Healthcare valuation: PE/EVEBITDA with regulatory and pipeline checks

Stored run vs live recompute

Score history

Factor attribution

Modelled fair value

Comparable companies

Business, management & trust

Issuer presentation review pending

How to read this Trust Score

Forensic breakdown

Trust positives

Trust risks

Continue researching Bilcare Limited

Important announcements & filings

Announcement under Regulation 30 (LODR)-Change in Management 15 Oct - Special resolutions failed; Mohan Bhandari and Kavita Bhansali remain non-executive directors, with Bhandari continuing as CEO.

Announcement under Regulation 30 (LODR)-Newspaper Publication 7 Sep

Board Meeting Outcome for Outcome Of Board Meeting 4 Sep - Board approved annual report, AGM notice, and 3-year executive director appointments; complied with NCLT deposit order.

Jun 2026 · Announcement under Regulation 30 (LODR)-Newspaper Publication 15 Aug - Bilcare Limited has informed about the Newspaper Publication of Quarterly Unaudited Standalone and Consolidated Financial Results for the Quarter ended 30th June 2026.

Jun 2026 · Announcement under Regulation 30 (LODR)-Change in Management 13 Aug - Q1 FY27 results approved; Mohan Bhandari appointed executive director, Sagar Baheti resigned, Mayur Dave appointed; Bilcare INC winding up proposed.

Jun 2026 · Announcement under Regulation 30 (LODR)-Resignation of Company Secretary / Compliance Officer 13 Aug - Q1 FY27 results approved; Mohan Bhandari appointed executive director; CS resigned, Mayur Dave appointed; Bilcare Inc winding up.

Announcement under Regulation 30 (LODR)-Newspaper Publication 23 Jun - Bilcare Limited has informed about Newspaper Publication regarding Postal Ballot Notice and Remote e-voting.

Announcement under Regulation 30 (LODR)-Newspaper Publication 1 Jun

Announcement Under Regulation 30 30 May - FY26 audited results approved; no dividend; redeemed Caprihans preference shares worth Rs15.6 crore and converted 10.4 lakh warrants.

Apr 2026 · Announcement under Regulation 30 (LODR)-Cessation 25 Apr - Madhuri Vaidya’s term ends 26 Apr 2026; Ashwini Hasabnis appointed independent director, committees reconstituted.

Apr 2026 · Announcement under Regulation 30 (LODR)-Change in Directorate 25 Apr - Adv. Ashwini Hasabnis appointed additional independent director from 25 Apr 2026; committees reconstituted.

Annual Report 2026